Dirigirse a las células madre cancerosas ARPC1B para sensibilizar el cáncer de páncreas al tratamiento con gemcitabina
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.Las células madre del cáncer de páncreas resistentes a la gemcitabina (CSC) pueden ser atacadas por CK-636. La terapia combinada con gemcitabina más CK-636 muestra efectos antitumorales superiores, superando la resistencia a los fármacos.
Área De La Ciencia
- En el campo de la oncología
- Biología del cáncer
- Descubrimiento de drogas
Sus Antecedentes
- El cáncer de páncreas contiene células madre cancerosas resistentes a la gemcitabina (CSCs) que expresan ARPC1B.
- El desarrollo de estrategias para superar la resistencia a la gemcitabina es crucial para mejorar los resultados de los pacientes.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...